472 related articles for article (PubMed ID: 24366758)
1. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Koizumi W; Kim YH; Fujii M; Kim HK; Imamura H; Lee KH; Hara T; Chung HC; Satoh T; Cho JY; Hosaka H; Tsuji A; Takagane A; Inokuchi M; Tanabe K; Okuno T; Ogura M; Yoshida K; Takeuchi M; Nakajima T;
J Cancer Res Clin Oncol; 2014 Feb; 140(2):319-28. PubMed ID: 24366758
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer.
Moriwaki T; Hirai S; Hironaka S; Amagai K; Soeda A; Sato M; Nihei T; Hirose M; Matsuda K; Ohkawara A; Yamaguchi T; Ozeki M; Mamiya T; Murashita T; Hyodo I
Gastric Cancer; 2014 Apr; 17(2):354-61. PubMed ID: 23852397
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
[TBL] [Abstract][Full Text] [Related]
4. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
Ryu MH; Baba E; Lee KH; Park YI; Boku N; Hyodo I; Nam BH; Esaki T; Yoo C; Ryoo BY; Song EK; Cho SH; Kang WK; Yang SH; Zang DY; Shin DB; Park SR; Shinozaki K; Takano T; Kang YK;
Ann Oncol; 2015 Oct; 26(10):2097-101. PubMed ID: 26216386
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
7. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
[TBL] [Abstract][Full Text] [Related]
8. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II Study of S-1 Plus Cisplatin Alternating With S-1 Plus Docetaxel in Patients With Advanced Gastric Cancer.
Hosokawa A; Ando T; Ogawa K; Ueda A; Yoshita H; Mihara H; Fujinami H; Kajiura S; Yabushita K; Horikawa N; Kobayashi Y; Yoshioka A; Origasa H; Sugiyama T
Am J Clin Oncol; 2018 Oct; 41(10):977-981. PubMed ID: 28930775
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002).
Takahari D; Ito S; Mizusawa J; Katayama H; Terashima M; Sasako M; Morita S; Nomura T; Yamada M; Fujiwara Y; Kimura Y; Ikeda A; Kadokawa Y; Sano T;
Gastric Cancer; 2020 Mar; 23(2):293-299. PubMed ID: 31515693
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of docetaxel and cisplatin plus S-1 for advanced gastric cancer.
Luo H; Yu Z; Gao H; Guan C; Xu M
J BUON; 2013; 18(1):154-61. PubMed ID: 23613401
[TBL] [Abstract][Full Text] [Related]
12. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer.
Kim HS; Ryu MH; Zang DY; Ryoo BY; Yang DH; Cho JW; Lim MS; Kim MJ; Han B; Choi DR; Kim JH; Jung JY; Song H; Park CK; Kang YK
Gastric Cancer; 2016 Apr; 19(2):579-585. PubMed ID: 25997815
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Kakeji Y; Oki E; Egashira A; Sadanaga N; Takahashi I; Morita M; Emi Y; Maehara Y
Oncology; 2009; 77(1):49-52. PubMed ID: 19556809
[TBL] [Abstract][Full Text] [Related]
16. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
17. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Yoshida K; Ninomiya M; Takakura N; Hirabayashi N; Takiyama W; Sato Y; Todo S; Terashima M; Gotoh M; Sakamoto J; Nishiyama M
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3402-7. PubMed ID: 16740764
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
Tanabe K; Suzuki T; Tokumoto N; Yamamoto H; Yoshida K; Ohdan H
World J Surg Oncol; 2010 May; 8():40. PubMed ID: 20482840
[TBL] [Abstract][Full Text] [Related]
20. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]